-
Sector Analysis
NewPurified Terephthalic Acid (PTA) Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Purified Terephthalic Acid (PTA) Capacity & Capital Expenditure (Capex) Overview The Purified Terephthalic Acid (PTA) capacity was 121.23 million tonnes per annum (mtpa) in 2023 and will increase at an AAGR of more than 5% from 2023 to 2028. In 2023, Iran, Saudi Arabia, and Turkey were the leading countries in the Middle East accounting for the total PTA capacity in the region. Large-scale production of polyester fiber in these regions, using PTA, drives its increasing consumption. This fiber finds...
-
Sector Analysis
Polyethylene Terephthalate (PET) Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Polyethylene Terephthalate (PET) Industry Capacity & CapEx Overview The polyethylene terephthalate (PET) industry capacity was 36.23 million tonnes per annum (mtpa) in 2023 and is expected to increase at an AAGR of more than 3% during 2023-2028. Around 17 planned and announced plants are slated to come online by 2028, primarily in Asia, Middle East and the Former Soviet Union (FSU). Additionally, the growing consumption of PET in packaging, food and beverage, as well as in textile industry will drive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YSON-001 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YSON-001 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YSON-001 in Metastatic Breast Cancer Drug Details: YS-ON-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YSON-001 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YSON-001 in Metastatic Liver Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YSON-001 in Metastatic Liver Cancer Drug Details: YS-ON-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YSON-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YSON-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YSON-001 in Solid Tumor Drug Details: YS-ON-001 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lemzoparlimab in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lemzoparlimab in B-Cell Non-Hodgkin Lymphoma Drug Details: TJC-4 (lemzoparlimab) is under...
-
Product Insights
Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Meningitis - Drugs In Development, 2023’, provides an overview of the Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Diarrhea – Drugs In Development, 2023
Global Markets Direct’s, ‘Diarrhea - Drugs In Development, 2023’, provides an overview of the Diarrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Varicella Zoster (HHV-3) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Drugs In Development, 2023’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...